text:
Pharmacokinetics
From Wikipedia, the free encyclopedia
Jump to: navigation, search
Pharmacokinetics (from Ancient Greek pharmakon "drug" and kinetikos "moving, putting in motion"; see chemical kinetics), sometimes abbreviated as PK, is a branch of pharmacology dedicated to determining the fate of substances administered to a living organism. The substances of interest include any chemical xenobiotic such as: pharmaceutical drugs, pesticides, food additives, cosmetics, etc. It attempts to analyze chemical metabolism and to discover the fate of a chemical from the moment that it is administered up to the point at which it is completely eliminated from the body. Pharmacokinetics is the study of how an organism affects a drug, whereas pharmacodynamics (PD) is the study of how the drug affects the organism. Both together influence dosing, benefit, and adverse effects, as seen in PK/PD models.
Contents
[hide]
1 Overview
2 Metrics
3 Pharmacokinetic models
3.1 Noncompartmental analysis
3.2 Compartmental analysis
3.3 Single-compartment model
3.4 Multi-compartmental models
3.5 Variable volume in time models
4 Bioavailability
5 LADME
6 Analysis
6.1 Bioanalytical methods
6.2 Mass spectrometry
7 Population pharmacokinetics
8 Clinical pharmacokinetics
9 Ecotoxicology
10 See also
11 References
12 External links
12.1 Software
12.2 Educational centres
Overview[edit]
Pharmacokinetics describes how the body affects a specific xenobiotic/chemical after administration through the mechanisms of absorption and distribution, as well as the metabolic changes of the substance in the body (e.g. by metabolic enzymes such as cytochrome P450 or glucuronosyltransferase enzymes), and the effects and routes of excretion of the metabolites of the drug.[1] Pharmacokinetic properties of chemicals are affected by the route of administration and the dose of administered drug. These may affect the absorption rate.[2]
Models have been developed to simplify conceptualization of the many processes that take place in the interaction between an organism and a chemical substance. One of these, the multi-compartmental model, is the most commonly used approximations to reality; however, the complexity involved in adding parameters with that modelling approach means that monocompartmental models and above all two compartmental models are the most-frequently used. The various compartments that the model is divided into are commonly referred to as the ADME scheme (also referred to as LADME if liberation is included as a separate step from absorption):
Liberation – the process of release of a drug from the pharmaceutical formulation.[3][4] See also IVIVC.
Absorption – the process of a substance entering the blood circulation.
Distribution – the dispersion or dissemination of substances throughout the fluids and tissues of the body.
Metabolism (or biotransformation, or inactivation) – the recognition by the organism that a foreign substance is present and the irreversible transformation of parent compounds into daughter metabolites.
Excretion – the removal of the substances from the body. In rare cases, some drugs irreversibly accumulate in body tissue.[citation needed]
The two phases of metabolism and excretion can also be grouped together under the title elimination. The study of these distinct phases involves the use and manipulation of basic concepts in order to understand the process dynamics. For this reason in order to fully comprehend the kinetics of a drug it is necessary to have detailed knowledge of a number of factors such as: the properties of the substances that act as excipients, the characteristics of the appropriate biological membranes and the way that substances can cross them, or the characteristics of the enzyme reactions that inactivate the drug.
All these concepts can be represented through mathematical formulas that have a corresponding graphical representation. The use of these models allows an understanding of the characteristics of a molecule, as well as how a particular drug will behave given information regarding some of its basic characteristics such as its acid dissociation constant (pKa), bioavailability and solubility, absorption capacity and distribution in the organism.
The model outputs for a drug can be used in industry (for example, in calculating bioequivalence when designing generic drugs) or in the clinical application of pharmacokinetic concepts. Clinical pharmacokinetics provides many performance guidelines for effective and efficient use of drugs for human-health professionals and in veterinary medicine.
Metrics[edit]
The following are the most commonly measured pharmacokinetic metrics:[5]
Characteristic
Description
Example value
Symbol
Formula
Dose Amount of drug administered. 500 mg D {\displaystyle D} Design parameter
Dosing interval Time between drug dose administrations. 24 h τ {\displaystyle \tau } Design parameter
Cmax The peak plasma concentration of a drug after administration. 60.9 mg/L C max {\displaystyle C_{\text{max}}} Direct measurement
tmax Time to reach Cmax. 3.9 h t max {\displaystyle t_{\text{max}}} Direct measurement
Cmin The lowest (trough) concentration that a drug reaches before the next dose is administered. 27.7 mg/L C min , ss {\displaystyle C_{{\text{min}},{\text{ss}}}} Direct measurement
Volume of distribution The apparent volume in which a drug is distributed (i.e., the parameter relating drug concentration in plasma to drug amount in the body). 6.0 L V d {\displaystyle V_{\text{d}}} = D C 0 {\displaystyle ={\frac {D}{C_{0}}}}
Concentration Amount of drug in a given volume of plasma. 83.3 mg/L C 0 , C ss {\displaystyle C_{0},C_{\text{ss}}} = D V d {\displaystyle ={\frac {D}{V_{\text{d}}}}}
Elimination half-life The time required for the concentration of the drug to reach half of its original value. 12 h t 1 2 {\displaystyle t_{\frac {1}{2}}} = ln  ( 2 ) k e {\displaystyle ={\frac {\ln(2)}{k_{\text{e}}}}}
Elimination rate constant The rate at which a drug is removed from the body. 0.0578 h−1 k e {\displaystyle k_{\text{e}}} = ln  ( 2 ) t 1 2 = C L V d {\displaystyle ={\frac {\ln(2)}{t_{\frac {1}{2}}}}={\frac {CL}{V_{\text{d}}}}}
Infusion rate Rate of infusion required to balance elimination. 50 mg/h k in {\displaystyle k_{\text{in}}} = C ss ⋅ C L {\displaystyle =C_{\text{ss}}\cdot CL}
Area under the curve The integral of the concentration-time curve (after a single dose or in steady state). 1,320 mg/L·h A U C 0 − ∞ {\displaystyle AUC_{0-\infty }} = ∫ 0 ∞ C d  t {\displaystyle =\int _{0}^{\infty }C\,\operatorname {d} t}
A U C τ , ss {\displaystyle AUC_{\tau ,{\text{ss}}}} = ∫ t t + τ C d  t {\displaystyle =\int _{t}^{t+\tau }C\,\operatorname {d} t}
Clearance The volume of plasma cleared of the drug per unit time. 0.38 L/h C L {\displaystyle CL} = V d ⋅ k e = D A U C {\displaystyle =V_{\text{d}}\cdot k_{\text{e}}={\frac {D}{AUC}}}
Bioavailability The systemically available fraction of a drug. 0.8 f {\displaystyle f} = A U C po ⋅ D iv A U C iv ⋅ D po {\displaystyle ={\frac {AUC_{\text{po}}\cdot D_{\text{iv}}}{AUC_{\text{iv}}\cdot D_{\text{po}}}}}
Fluctuation Peak trough fluctuation within one dosing interval at steady state. 41.8 % % P T F {\displaystyle \%PTF} = C max , ss − C min , ss C av , ss ⋅ 100 {\displaystyle ={\frac {C_{{\text{max}},{\text{ss}}}-C_{{\text{min}},{\text{ss}}}}{C_{{\text{av}},{\text{ss}}}}}\cdot 100}
where
C av , ss = 1 τ A U C τ , ss {\displaystyle C_{{\text{av}},{\text{ss}}}={\frac {1}{\tau }}AUC_{\tau ,{\text{ss}}}}
[
v
t
e
]
In pharmacokinetics, steady state refers to the situation where the overall intake of a drug is fairly in dynamic equilibrium with its elimination. In practice, it is generally considered that steady state is reached when a time of 4 to 5 times the half-life for a drug after regular dosing is started.
The following graph depicts a typical time course of drug plasma concentration and illustrates main pharmacokinetic metrics:
The time course of drug plasma concentrations over 96 hours following oral administrations every 24 hours. Note that the AUC in steady state equals AUC∞ after the first dose.
Pharmacokinetic models[edit]
Pharmacokinetic modelling is performed by noncompartmental or compartmental methods. Noncompartmental methods estimate the exposure to a drug by estimating the area under the curve of a concentration-time graph. Compartmental methods estimate the concentration-time graph using kinetic models. Noncompartmental methods are often more versatile in that they do not assume any specific compartmental model and produce accurate results also acceptable for bioequivalence studies. The final outcome of the transformations that a drug undergoes in an organism and the rules that determine this fate depend on a number of interrelated factors. A number of functional models have been developed in order to simplify the study of pharmacokinetics. These models are based on a consideration of an organism as a number of related compartments. The simplest idea is to think of an organism as only one homogenous compartment. This monocompartmental model presupposes that blood plasma concentrations of the drug are a true reflection of the drug’s concentration in other fluids or tissues and that the elimination of the drug is directly proportional to the drug’s concentration in the organism (first order kinetics).
However, these models do not always truly reflect the real situation within an organism. For example, not all body tissues have the same blood supply, so the distribution of the drug will be slower in these tissues than in others with a better blood supply. In addition, there are some tissues (such as the brain tissue) that present a real barrier to the distribution of drugs, that can be breached with greater or lesser ease depending on the drug’s characteristics. If these relative conditions for the different tissue types are considered along with the rate of elimination, the organism can be considered to be acting like two compartments: one that we can call the central compartment that has a more rapid distribution, comprising organs and systems with a well-developed blood supply; and a peripheral compartment made up of organs with a lower blood flow. Other tissues, such as the brain, can occupy a variable position depending on a drug’s ability to cross the barrier that separates the organ from the blood supply.
This two compartment model will vary depending on which compartment elimination occurs in. The most common situation is that elimination occurs in the central compartment as the liver and kidneys are organs with a good blood supply. However, in some situations it may be that elimination occurs in the peripheral compartment or even in both. This can mean that there are three possible variations in the two compartment model, which still do not cover all possibilities.[6]
This model may not be applicable in situations where some of the enzymes responsible for metabolizing the drug become saturated, or where an active elimination mechanism is present that is independent of the drug's plasma concentration. In the real world each tissue will have its own distribution characteristics and none of them will be strictly linear. If we label the drug’s volume of distribution within the organism VdF and its volume of distribution in a tissue VdT the former will be described by an equation that takes into account all the tissues that act in different ways, that is:
V d F = V d T 1 + V d T 2 + V d T 3 + ⋯ + V d T n {\displaystyle Vd_{F}=Vd_{T1}+Vd_{T2}+Vd_{T3}+\cdots +Vd_{Tn}\,}
This represents the multi-compartment model with a number of curves that express complicated equations in order to obtain an overall curve. A number of computer programs have been developed to plot these equations.[6] However complicated and precise this model may be, it still does not truly represent reality despite the effort involved in obtaining various distribution values for a drug. This is because the concept of distribution volume is a relative concept that is not a true reflection of reality. The choice of model therefore comes down to deciding which one offers the lowest margin of error for the drug involved.
Graph representing the monocompartmental action model.
Noncompartmental analysis[edit]
Noncompartmental PK analysis is highly dependent on estimation of total drug exposure. Total drug exposure is most often estimated by area under the curve (AUC) methods, with the trapezoidal rule (numerical integration) the most common method. Due to the dependence on the length of x in the trapezoidal rule, the area estimation is highly dependent on the blood/plasma sampling schedule. That is, the closer time points are, the closer the trapezoids reflect the actual shape of the concentration-time curve.
Compartmental analysis[edit]
Compartmental PK analysis uses kinetic models to describe and predict the concentration-time curve. PK compartmental models are often similar to kinetic models used in other scientific disciplines such as chemical kinetics and thermodynamics. The advantage of compartmental over some noncompartmental analyses is the ability to predict the concentration at any time. The disadvantage is the difficulty in developing and validating the proper model. Compartment-free modelling based on curve stripping does not suffer this limitation. The simplest PK compartmental model is the one-compartmental PK model with IV bolus administration and first-order elimination. The most complex PK models (called PBPK models) rely on the use of physiological information to ease development and validation.
Single-compartment model[edit]
Linear pharmacokinetics is so-called because the graph of the relationship between the various factors involved (dose, blood plasma concentrations, elimination, etc.) gives a straight line or an approximation to one. For drugs to be effective they need to be able to move rapidly from blood plasma to other body fluids and tissues.
The change in concentration over time can be expressed as C = C initial × e − k el × t {\displaystyle C=C_{\text{initial}}\times e^{-k_{\text{el}}\times t}}
Multi-compartmental models[edit]
Graphs for absorption and elimination for a non-linear pharmacokinetic model.
The graph for the non-linear relationship between the various factors is represented by a curve; the relationships between the factors can then be found by calculating the dimensions of different areas under the curve. The models used in non-linear pharmacokinetics are largely based on Michaelis–Menten kinetics. A reaction’s factors of non-linearity include the following:
Multiphasic absorption: Drugs injected intravenously are removed from the plasma through two primary mechanisms: (1) Distribution to body tissues and (2) metabolism + excretion of the drugs. The resulting decrease of the drug's plasma concentration follows a biphasic pattern (see figure).
Plasma drug concentration vs time after an IV dose
Alpha phase: An initial phase of rapid decrease in plasma concentration. The decrease is primarily attributed to drug distribution from the central compartment (circulation) into the peripheral compartments (body tissues). This phase ends when a pseudo-equilibrium of drug concentration is established between the central and peripheral compartments.
Beta phase: A phase of gradual decrease in plasma concentration after the alpha phase. The decrease is primarily attributed to drug metabolism and excretion.[7]
Additional phases (gamma, delta, etc.) are sometimes seen.[8]
A drug’s characteristics make a clear distinction between tissues with high and low blood flow.
Enzymatic saturation: When the dose of a drug whose elimination depends on biotransformation is increased above a certain threshold the enzymes responsible for its metabolism become saturated. The drug’s plasma concentration will then increase disproportionately and its elimination will no longer be constant.
Induction or enzymatic inhibition: Some drugs have the capacity to inhibit or stimulate their own metabolism, in negative or positive feedback reactions. As occurs with fluvoxamine, fluoxetine and phenytoin. As larger doses of these pharmaceuticals are administered the plasma concentrations of the unmetabolized drug increases and the elimination half-life increases. It is therefore necessary to adjust the dose or other treatment parameters when a high dosage is required.
The kidneys can also establish active elimination mechanisms for some drugs, independent of plasma concentrations.
It can therefore be seen that non-linearity can occur because of reasons that affect the entire pharmacokinetic sequence: absorption, distribution, metabolism and elimination.
Variable volume in time models[edit]
Variable volume pharmacokinetic models can be drug centered models that imply a volume of drug distribution to be that volume in which the drug is distributed at that elapsed time following drug administration.[9][10] Another possibility occurs when the body volume is changing in time, which would occur, for example, during dialysis when the volume in which a drug can be distributed is itself changing in time.[11]
Bioavailability[edit]
Main article: Bioavailability
At a practical level, a drug’s bioavailability can be defined as the proportion of the drug that reaches its site of action. From this perspective the intravenous administration of a drug provides the greatest possible bioavailability, and this method is considered to yield a bioavailability of 1 (or 100%). Bioavailability of other delivery methods is compared with that of intravenous injection («absolute bioavailability») or to a standard value related to other delivery methods in a particular study («relative bioavailability»).
B A = [ A B C ] P ⋅ D I V [ A B C ] I V ⋅ D P {\displaystyle B_{A}={\frac {[ABC]_{P}\cdot D_{IV}}{[ABC]_{IV}\cdot D_{P}}}}
B R = [ A B C ] A ⋅ dose B [ A B C ] B ⋅ dose A {\displaystyle {\mathit {B}}_{R}={\frac {[ABC]_{A}\cdot {\text{dose}}_{B}}{[ABC]_{B}\cdot {\text{dose}}_{A}}}}
Once a drug’s bioavailability has been established it is possible to calculate the changes that need to be made to its dosage in order to reach the required blood plasma levels. Bioavailability is therefore a mathematical factor for each individual drug that influences the administered dose. It is possible to calculate the amount of a drug in the blood plasma that has a real potential to bring about its effect using the formula: D e = B ⋅ D a {\displaystyle De=B\cdot Da\,} ; where De is the effective dose, B bioavailability and Da the administered dose.
Therefore, if a drug has a bioavailability of 0.8 (or 80%) and it is administered in a dose of 100 mg, the equation will demonstrate the following:
De = 0.8 × 100 mg = 80 mg
That is the 100 mg administered represents a blood plasma concentration of 80 mg that has the capacity to have a pharmaceutical effect.
Different forms of tablets, which will have different pharmacokinetic behaviours after their administration.
This concept depends on a series of factors inherent to each drug, such as:[12]
Pharmaceutical form
Chemical form
Route of administration
Stability
Metabolism
These concepts, which are discussed in detail in their respective titled articles, can be mathematically quantified and integrated to obtain an overall mathematical equation:
D e = Q ⋅ D a ⋅ B {\displaystyle De=Q\cdot Da\cdot B\,}
where Q is the drug’s purity.[12]
V a = D a ⋅ B ⋅ Q τ {\displaystyle Va={\frac {Da\cdot B\cdot Q}{\tau }}}
where V a {\displaystyle Va} is the drug’s rate of administration and τ {\displaystyle \tau } is the rate at which the absorbed drug reaches the circulatory system.
Finally, using the Henderson-Hasselbalch equation, and knowing the drug’s p K a {\displaystyle pKa\,} (pH at which there is an equilibrium between its ionized and non ionized molecules), it is possible to calculate the non ionized concentration of the drug and therefore the concentration that will be subject to absorption:
p H = p K a + log  B A {\displaystyle pH=pKa+\log {\frac {B}{A}}}
When two drugs have the same bioavailability, they are said to be biological equivalents or bioequivalents. This concept of bioequivalence is important because it is currently used as a yardstick in the authorization of generic drugs in many countries.
LADME[edit]
Main article: ADME
A number of phases occur once the drug enters into contact with the organism, these are described using the acronym LADME:
Liberation of the active substance from the delivery system,
Absorption of the active substance by the organism,
Distribution through the blood plasma and different body tissues,
Metabolism that is, inactivation of the xenobiotic substance, and finally
Excretion or elimination of the substance or the products of its metabolism.
Some textbooks combine the first two phases as the drug is often administered in an active form, which means that there is no liberation phase. Others include a phase that combines distribution, metabolism and excretion into a disposition phase. Other authors include the drug’s toxicological aspect in what is known as ADME-Tox or ADMET.
Each of the phases is subject to physico-chemical interactions between a drug and an organism, which can be expressed mathematically. Pharmacokinetics is therefore based on mathematical equations that allow the prediction of a drug’s behavior and which place great emphasis on the relationships between drug plasma concentrations and the time elapsed since the drug’s administration.
Analysis[edit]
Bioanalytical methods[edit]
Bioanalytical methods are necessary to construct a concentration-time profile. Chemical techniques are employed to measure the concentration of drugs in biological matrix, most often plasma. Proper bioanalytical methods should be selective and sensitive. For example, microscale thermophoresis can be used to quantify how the biological matrix/liquid affects the affinity of a drug to its target.[13][14]
Mass spectrometry[edit]
Pharmacokinetics is often studied using mass spectrometry because of the complex nature of the matrix (often plasma or urine) and the need for high sensitivity to observe concentrations after a low dose and a long time period. The most common instrumentation used in this application is LC-MS with a triple quadrupole mass spectrometer. Tandem mass spectrometry is usually employed for added specificity. Standard curves and internal standards are used for quantitation of usually a single pharmaceutical in the samples. The samples represent different time points as a pharmaceutical is administered and then metabolized or cleared from the body. Blank samples taken before administration are important in determining background and ensuring data integrity with such complex sample matrices. Much attention is paid to the linearity of the standard curve; however it is common to use curve fitting with more complex functions such as quadratics since the response of most mass spectrometers is not linear across large concentration ranges.[15][16][17]
There is currently considerable interest in the use of very high sensitivity mass spectrometry for microdosing studies, which are seen as a promising alternative to animal experimentation.[18]
Population pharmacokinetics[edit]
Population pharmacokinetics is the study of the sources and correlates of variability in drug concentrations among individuals who are the target patient population receiving clinically relevant doses of a drug of interest.[19][20][21] Certain patient demographic, pathophysiological, and therapeutical features, such as body weight, excretory and metabolic functions, and the presence of other therapies, can regularly alter dose-concentration relationships. For example, steady-state concentrations of drugs eliminated mostly by the kidney are usually greater in patients suffering from renal failure than they are in patients with normal renal function receiving the same drug dosage. Population pharmacokinetics seeks to identify the measurable pathophysiologic factors that cause changes in the dose-concentration relationship and the extent of these changes so that, if such changes are associated with clinically significant shifts in the therapeutic index, dosage can be appropriately modified. An advantage of population pharmacokinetic modelling is its ability to analyse sparse data sets (sometimes only one concentration measurement per patient is available).
Clinical pharmacokinetics[edit]
Clinical pharmacokinetics (arising from the clinical use of population pharmacokinetics) is the direct application to a therapeutic situation of knowledge regarding a drug’s pharmacokinetics and the characteristics of a population that a patient belongs to (or can be ascribed to).
An example is the relaunch of the use of ciclosporin as an immunosuppressor to facilitate organ transplant. The drug's therapeutic properties were initially demonstrated, but it was almost never used after it was found to cause nephrotoxicity in a number of patients.[22] However, it was then realized that it was possible to individualize a patient's dose of ciclosporin by analysing the patients plasmatic concentrations (pharmacokinetic monitoring). This practice has allowed this drug to be used again and has facilitated a great number of organ transplants.
Clinical monitoring is usually carried out by determination of plasma concentrations as this data is usually the easiest to obtain and the most reliable. The main reasons for determining a drug’s plasma concentration include:[23]
Narrow therapeutic range (difference between toxic and therapeutic concentrations)
High toxicity
High risk to life.
Drugs where pharmacokinetic monitoring is recommended include:
Medications for which monitoring is recommended
Antiepileptic medication
+ Phenytoin
+ Carbamazepine
+ Valproic acid
+ Lamotrigine
+ Ethosuximide
+ Phenobarbital
+ Primidone
Cardioactive medication
+ Digoxin
+ Lidocaine
Immunosuppressor medication
+ Ciclosporin
+ Tacrolimus
+ Sirolimus
+ Everolimus
+ Mycophenolate
Antibiotic medication
+ Gentamicin
+ Tobramycin
+ Amikacin
+ Vancomycin
Bronchodilator medication
+ Theophylline
Cytostatic medication
+ Methotrexate
+ 5-Fluorouracil
+ Irinotecan
* Antiviral (HIV) medication
+ Efavirenz
+ Tenofovir
+ Ritonavir
Coagulation factors
+ Factor VIII,
+ Factor IX,
+ Factor VIIa,
+ Factor XI
Ecotoxicology[edit]
Ecotoxicology is the branch of science that deals with the nature, effects, and interactions of substances that are harmful to the environment.[24][25]
See also[edit]
Blood alcohol concentration
Biological half-life
Bioavailability
Enzyme kinetics
Pharmacodynamics
Idiosyncratic drug reaction
Drug interaction
Patlak plot
Pharmacometrics
Pharmacy
Bioequivalence
Generic drugs
Physiologically based pharmacokinetic modelling
Plateau principle
Toxicokinetics
References[edit]
Jump up ^ Pharmacokinetics. (2006). In Mosby's Dictionary of Medicine, Nursing & Health Professions. Philadelphia, PA: Elsevier Health Sciences. Retrieved December 11, 2008, from http://www.credoreference.com/entry/6686418
Jump up ^ Knights K, Bryant B (2002). Pharmacology for Health Professionals. Amsterdam: Elsevier. ISBN 0-7295-3664-5.
Jump up ^ Koch HP, Ritschel WA (1986). "Liberation". Synopsis der Biopharmazie und Pharmakokinetik (in German). Landsberg, München: Ecomed. pp. 99–131. ISBN 3-609-64970-4.
Jump up ^ Ruiz-Garcia A, Bermejo M, Moss A, Casabo VG (February 2008). "Pharmacokinetics in drug discovery". Journal of Pharmaceutical Sciences. 97 (2): 654–90. doi:10.1002/jps.21009. PMID 17630642.
Jump up ^ AGAH working group PHARMACOKINETICS (2004-02-16). "Collection of terms, symbols, equations, and explanations of common pharmacokinetic and pharmacodynamic parameters and some statistical functions" (PDF). Arbeitsgemeinschaft für Angewandte Humanpharmakologie (AGAH) (Association for Applied Human Pharmacology). Retrieved 2011-04-04.
^ Jump up to: a b Milo Gibaldi, Donald Perrier. FarmacocinéticaReverté 1982 pages 1–10. ISBN 84-291-5535-X, 9788429155358
Jump up ^ Gill SC, Moon-Mcdermott L, Hunt TL, Deresinski S, Blaschke T, Sandhaus RA (Sep 1999). "Phase I Pharmacokinetics of Liposomal Amikacin (MiKasome) in Human Subjects: Dose Dependence and Urinary Clearance". Abstr Intersci Conf Antimicrob Agents Chemother. 39: 33 (abstract no. 1195).
Jump up ^ Weiner D, Gabrielsson J (2000). "PK24 – Non-linear kinetics – flow II". Pharmacokinetic/pharmacodynamic data analysis: concepts and applications. Apotekarsocieteten. pp. 527–36. ISBN 91-86274-92-9.
Jump up ^ Niazi S (March 1976). "Volume of distribution as a function of time". Journal of Pharmaceutical Sciences. 65 (3): 452–4. doi:10.1002/jps.2600650339. PMID 1263103.
Jump up ^ Wesolowski CA, Wesolowski MJ, Babyn PS, Wanasundara SN (2016). "Time Varying Apparent Volume of Distribution and Drug Half-Lives Following Intravenous Bolus Injections". PLOS ONE. 11 (7): e0158798. doi:10.1371/journal.pone.0158798. PMC 4942076  . PMID 27403663.
Jump up ^ Kim DK, Lee JC, Lee H, Joo KW, Oh KH, Kim YS, Yoon HJ, Kim HC (April 2016). "Calculation of the clearance requirements for the development of a hemodialysis-based wearable artificial kidney". Hemodialysis International. International Symposium on Home Hemodialysis. 20 (2): 226–34. doi:10.1111/hdi.12343. PMID 26245302.
^ Jump up to: a b Michael E. Winter, Mary Anne Koda-Kimple, Lloyd Y. Young, Emilio Pol Yanguas Farmacocinética clínica básica Ediciones Díaz de Santos, 1994 pgs. 8–14 ISBN 84-7978-147-5, 9788479781477 (in Spanish)
Jump up ^ Baaske P, Wienken CJ, Reineck P, Duhr S, Braun D (March 2010). "Optical thermophoresis for quantifying the buffer dependence of aptamer binding". Angewandte Chemie. 49 (12): 2238–41. doi:10.1002/anie.200903998. PMID 20186894. Lay summary – Phsyorg.com.
Jump up ^ Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S (October 2010). "Protein-binding assays in biological liquids using microscale thermophoresis". Nature Communications. 1 (7): 100. Bibcode:2010NatCo...1E.100W. doi:10.1038/ncomms1093. PMID 20981028.
Jump up ^ Hsieh Y, Korfmacher WA (June 2006). "Increasing speed and throughput when using HPLC-MS/MS systems for drug metabolism and pharmacokinetic screening". Current Drug Metabolism. 7 (5): 479–89. doi:10.2174/138920006777697963. PMID 16787157.
Jump up ^ Covey TR, Lee ED, Henion JD (October 1986). "High-speed liquid chromatography/tandem mass spectrometry for the determination of drugs in biological samples". Analytical Chemistry. 58 (12): 2453–60. doi:10.1021/ac00125a022. PMID 3789400.
Jump up ^ Covey TR, Crowther JB, Dewey EA, Henion JD (February 1985). "Thermospray liquid chromatography/mass spectrometry determination of drugs and their metabolites in biological fluids". Analytical Chemistry. 57 (2): 474–81. doi:10.1021/ac50001a036. PMID 3977076.
Jump up ^ Committee for Medicinal Products for Human Use (CHMP) (December 2009). "ICH guideline M3(R2) on non-clinical safety studies for the conduct of human clinical trials and marketing authorisation for pharmaceuticals" (PDF). European Medicines Agency, Evaluation of Medicines for Human Use. EMA/CPMP/ICH/286/1995. Retrieved 4 May 2013.
Jump up ^ Sheiner LB, Rosenberg B, Marathe VV (October 1977). "Estimation of population characteristics of pharmacokinetic parameters from routine clinical data". Journal of Pharmacokinetics and Biopharmaceutics. 5 (5): 445–79. doi:10.1007/BF01061728. PMID 925881.
Jump up ^ Sheiner LB, Beal S, Rosenberg B, Marathe VV (September 1979). "Forecasting individual pharmacokinetics". Clinical Pharmacology and Therapeutics. 26 (3): 294–305. doi:10.1002/cpt1979263294. PMID 466923.
Jump up ^ Bonate PL (October 2005). "Recommended reading in population pharmacokinetic pharmacodynamics". The AAPS Journal. 7 (2): E363–73. doi:10.1208/aapsj070237. PMC 2750974  . PMID 16353916.
Jump up ^ R. García del Moral, M. Andújar y F. O'Valle Mecanismos de nefrotoxicidad por ciclosporina A a nivel celular[permanent dead link] (in Spanish). NEFROLOGIA. Vol. XV. Supplement 1, 1995. Consulted 23 February 2008.
Jump up ^ Joaquín Herrera Carranza Manual de farmacia clínica y Atención Farmacéutica (in Spanish). Published by Elsevier España, 2003; page 159. ISBN 84-8174-658-4
Jump up ^ Jager T, Albert C, Preuss TG, Ashauer R (April 2011). "General unified threshold model of survival--a toxicokinetic-toxicodynamic framework for ecotoxicology". Environmental Science & Technology. 45 (7): 2529–40. Bibcode:2011EnST...45.2529J. doi:10.1021/es103092a. PMID 21366215.
Jump up ^ Ashauer R. "Toxicokinetic-Toxicodynamic Models – Ecotoxicology and Models". Swiss Federal Institute of Aquatic Science and Technology. Archived from the original on 2012-04-05. Retrieved 2011-12-03.
External links[edit]
This article's use of external links may not follow Wikipedia's policies or guidelines. Please improve this article by removing excessive or inappropriate external links, and converting useful links where appropriate into footnote references. (May 2016) (Learn how and when to remove this template message)
Software[edit]
Noncompartmental
Freeware: bear and PK for R
Commercial: MLAB, EquivTest, Kinetica, MATLAB/SimBiology, PKMP,Phoenix/WinNonlin, PK Solutions, RapidNCA.
Compartment based
Freeware: ADAPT, Boomer (GUI), SBPKPD.org (Systems Biology Driven Pharmacokinetics and Pharmacodynamics), WinSAAM, PKfit for R, PharmaCalc and PharmaCalcCL, Java applications.
Commercial: Imalytics, Kinetica, MATLAB/SimBiology, Phoenix/WinNonlin, PK Solutions, PottersWheel, ProcessDB, SAAM II.
Physiologically based
Freeware: MCSim
Commercial: acslX, Cloe PK, GastroPlus, MATLAB/SimBiology, PK-Sim, ProcessDB, Simcyp, Entelos PhysioLab Phoenix/WinNonlin, ADME Workbench.
Population PK
Freeware: WinBUGS, ADAPT, S-ADAPT / SADAPT-TRAN, Boomer, PKBugs, Pmetrics for R.
Commercial: Kinetica, MATLAB/SimBiology, Monolix, NONMEM, Phoenix/NLME, PopKinetics for SAAM II, USC*PACK, Navigator Workbench.
Simulation
All model based software above.
Freeware: COPASI, Berkeley Madonna, MEGen.
Educational centres[edit]
Global centres with the highest profiles for providing in-depth training include the Universities of Buffalo, Florida, Gothenburg, Leiden, Otago, San Francisco, Beijing, Tokyo, Uppsala, Washington, Manchester, Monash University, and University of Sheffield.[1]
[hide]
v
t
e
Concepts in pharmacology
Pharmacokinetics
(L)ADME: (Liberation)
Absorption
Distribution
Metabolism
Excretion (Clearance)
Loading dose
Volume of distribution (Initial)
Rate of infusion
Compartment
Bioequivalence
Bioavailability
Onset of action
Biological half-life
Mean residence time
Plasma protein binding
Therapeutic index (Median lethal dose, Effective dose)
Pharmacodynamics
Mechanism of action
Toxicity (Neurotoxicology)
Dose–response relationship (Efficacy, Potency)
Antimicrobial pharmacodynamics: Minimum inhibitory concentration (Bacteriostatic)
Minimum bactericidal concentration (Bactericide)
Agonism and
antagonism
Agonist: Inverse agonist
Irreversible agonist
Partial agonist
Superagonist
Physiological agonist
Antagonist: Competitive antagonist
Irreversible antagonist
Physiological antagonist
Other: Binding
Affinity
Binding selectivity
Functional selectivity
Other
Drug tolerance: Tachyphylaxis
Drug resistance: Antibiotic resistance
Multiple drug resistance
Drug discovery
strategies
Classical pharmacology
Reverse pharmacology
Related
fields/subfields
Pharmacogenetics
Pharmacogenomics
Neuropsychopharmacology (Neuropharmacology, Psychopharmacology)
Authority control
NDL: 01033752
Jump up ^ Tucker GT (June 2012). "Research priorities in pharmacokinetics". British Journal of Clinical Pharmacology. 73 (6): 924–6. doi:10.1111/j.1365-2125.2012.04238.x. PMC 3391520  . PMID 22360418.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Pharmacokinetics&oldid=826736959"
Categories:
Pharmacokinetics
Pharmacy
Life sciences industry
Hidden categories:
CS1 German-language sources (de)
All articles with dead external links
Articles with dead external links from September 2017
Articles with permanently dead external links
All articles with unsourced statements
Articles with unsourced statements from February 2018
Wikipedia external links cleanup from May 2016
Wikipedia spam cleanup from May 2016
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Article
Talk
Variants
Views
Read
Edit
View history
More
Search
Navigation
Main page
Contents
Featured content
Current events
Random article
Donate to Wikipedia
Wikipedia store
Interaction
Help
About Wikipedia
Community portal
Recent changes
Contact page
Tools
What links here
Related changes
Upload file
Special pages
Permanent link
Page information
Wikidata item
Cite this page
Print/export
Create a book
Download as PDF
Printable version
In other projects
Wikimedia Commons
Languages
العربية
Български
Català
Čeština
Dansk
Deutsch
Eesti
Ελληνικά
Español
فارسی
Français
Galego
한국어
Hrvatski
Bahasa Indonesia
Italiano
עברית
Latviešu
Lietuvių
Lumbaart
Македонски
मराठी
Nederlands
日本語
Norsk
Polski
Português
Русский
Scots
Simple English
Slovenščina
Српски / srpski
Srpskohrvatski / српскохрватски
Suomi
Svenska
ไทย
Türkçe
Українська
Tiếng Việt
中文
Edit links
This page was last edited on 20 February 2018, at 19:03.
Text is available under the Creative Commons Attribution-ShareAlike License; additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy. Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc., a non-profit organization.
Privacy policy
About Wikipedia
Disclaimers
Contact Wikipedia
Developers
Cookie statement
Mobile view
Enable previews

values: mw-page-base noprint

values: mw-head-base noprint

values: firstHeading firstHeading en

values: siteSub noprint

values: jump-to-nav mw-jump

attrs: href class title

values:
/wiki/Pharmaceutical_drug
mw-redirect
Pharmaceutical drug

values: /wiki/Excreted mw-redirect Excreted

values:
/wiki/Absorption_(pharmacokinetics)
mw-redirect
Absorption (pharmacokinetics)

values:
/wiki/Body_tissue
mw-redirect
Body tissue

values: This is a strong claim and should be backed by literature reference(s) (February 2018)

values:
noprint Inline-Template Template-Fact
white-space:nowrap;

values: vertical-align: -0.338ex; width:1.924ex; height:2.176ex;

values: vertical-align: -0.338ex; width:1.202ex; height:1.676ex;

values: vertical-align: -0.671ex; width:4.953ex; height:2.509ex;

values: vertical-align: -0.671ex; width:4.131ex; height:2.343ex;

values: vertical-align: -1.005ex; width:6.387ex; height:2.843ex;

values: vertical-align: -0.671ex; width:2.501ex; height:2.509ex;

values: vertical-align: -2.338ex; width:6.005ex; height:5.676ex;

values: vertical-align: -0.671ex; width:6.94ex; height:2.509ex;

values: vertical-align: -2.338ex; width:5.791ex; height:5.676ex;

values: vertical-align: -2.171ex; width:2.575ex; height:3.843ex;

values: vertical-align: -2.338ex; width:8.201ex; height:6.176ex;

values: vertical-align: -0.671ex; width:2.173ex; height:2.509ex;

values: vertical-align: -3.671ex; width:15.484ex; height:7.509ex;

values: vertical-align: -0.671ex; width:2.815ex; height:2.509ex;

values: vertical-align: -0.671ex; width:10.671ex; height:2.509ex;

values: vertical-align: -0.671ex; width:9.163ex; height:2.509ex;

values: vertical-align: -2.338ex; width:12.24ex; height:5.843ex;

values: =\int _{0}^{\infty }C\,\operatorname {d} t

values: vertical-align: -1.005ex; width:8.023ex; height:2.843ex;

values: vertical-align: -2.338ex; width:13.319ex; height:6.176ex;

values: =\int _{t}^{t+\tau }C\,\operatorname {d} t

values:
/wiki/Clearance_(medicine)
mw-redirect
Clearance (medicine)

values: vertical-align: -0.338ex; width:3.349ex; height:2.176ex;

values: vertical-align: -2.005ex; width:18.034ex; height:5.343ex;

values: vertical-align: -0.671ex; width:1.279ex; height:2.509ex;

values: vertical-align: -2.671ex; width:15.606ex; height:6.509ex;

values: vertical-align: -0.338ex; width:7.058ex; height:2.343ex;

values: vertical-align: -2.671ex; width:24.39ex; height:6.509ex;

values: vertical-align: -1.838ex; width:18.497ex; height:5.176ex;

values:
/wiki/First_order_kinetics
mw-redirect
First order kinetics

values: vertical-align: -0.671ex; width:43.024ex; height:2.509ex;

values: vertical-align: -0.671ex; width:20.256ex; height:3.009ex;

values: Edit section: Multi-compartmental models

values: Edit section: Variable volume in time models

values: vertical-align: -2.671ex; width:21.125ex; height:6.509ex;

values: vertical-align: -2.671ex; width:22.645ex; height:6.509ex;

values: vertical-align: -0.338ex; width:13.09ex; height:2.176ex;

values: vertical-align: -0.671ex; width:16.608ex; height:2.509ex;

values: {\displaystyle Va={\frac {Da\cdot B\cdot Q}{\tau }}}

values: vertical-align: -1.838ex; width:17.066ex; height:5.343ex;

values: vertical-align: -0.338ex; width:3.017ex; height:2.176ex;

values:
/wiki/Henderson-Hasselbalch_equation
mw-redirect
Henderson-Hasselbalch equation

values: vertical-align: -0.671ex; margin-left: -0.089ex; width:4.942ex; height:2.509ex;

values: {\displaystyle pH=pKa+\log {\frac {B}{A}}}

values: vertical-align: -2.005ex; margin-left: -0.089ex; width:19.685ex; height:5.343ex;

values:
/wiki/Biological_matrix
mw-redirect
Biological matrix

values:
/wiki/Animal_experimentation
mw-redirect
Animal experimentation

values: Edit section: Population pharmacokinetics

values:
/wiki/Valproic_acid
mw-redirect
Valproic acid

values:
/wiki/Coagulation_factor
mw-redirect
Coagulation factor

values:
/wiki/Blood_alcohol_concentration
mw-redirect
Blood alcohol concentration

values:
/wiki/Generic_drugs
mw-redirect
Generic drugs

values: Physiologically based pharmacokinetic modelling

values:
nofollow
external text
//doi.org/10.1002%2Fjps.21009

values:
/wiki/PubMed_Identifier
mw-redirect
PubMed Identifier

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/17630642

values:
nofollow
external text
//doi.org/10.1002%2Fjps.2600650339

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/1263103

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/27403663

values:
nofollow
external text
//doi.org/10.1111%2Fhdi.12343

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/26245302

values:
nofollow
external text
//doi.org/10.1002%2Fanie.200903998

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20186894

values:
nofollow
external text
//doi.org/10.1038%2Fncomms1093

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/20981028

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16787157

values:
nofollow
external text
//doi.org/10.1021%2Fac00125a022

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3789400

values:
nofollow
external text
//doi.org/10.1021%2Fac50001a036

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/3977076

values:
nofollow
external text
//doi.org/10.1007%2FBF01061728

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/925881

values:
nofollow
external text
//doi.org/10.1002%2Fcpt1979263294

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/466923

values:
nofollow
external text
//doi.org/10.1208%2Faapsj070237

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/16353916

values:
nofollow
external text
//doi.org/10.1021%2Fes103092a

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/21366215

values: -moz-column-width: 30em; -webkit-column-width: 30em; column-width: 30em; list-style-type: decimal;

values: plainlinks metadata ambox ambox-style ambox-external_links

values:
nofollow
http://pkpd.kmu.edu.tw/bear/
external text

values:
nofollow
http://aplanalyst.com/
external text

values:
nofollow
http://bmsr.usc.edu/software/adapt/
external text

values:
nofollow
http://www.boomer.org/
external text

values:
nofollow
http://pkpd.kmu.edu.tw/jguib/
external text

values:
nofollow
http://www.sbpkpd.org/
external text

values:
nofollow
http://www.biopharmacy.ethz.ch/
external text

values:
nofollow
http://depts.washington.edu/saam2/
external text

values:
nofollow
https://www.gnu.org/software/mcsim/
external text

values:
nofollow
http://www.acslx.com/
external text

values:
nofollow
http://www.cloegateway.com/
external text

values:
nofollow
http://www.simcyp.com/
external text

values:
nofollow
http://www.admewb.com/
external text

values:
nofollow
external text
http://www.lapk.org/pmetrics.php

values:
nofollow
http://lixoft.com/products/monolix/
external text

values:
nofollow
external text
http://www.lapk.org/software.php

values:
nofollow
http://xnet.hsl.gov.uk/megen/
external text

values:
/wiki/Buffalo_University
mw-redirect
Buffalo University

values:
/wiki/Florida_University
mw-redirect
Florida University

values:
/wiki/Otago_University
mw-redirect
Otago University

values:
/wiki/Manchester_University
mw-redirect
Manchester University

values:
/wiki/Sheffield_University
mw-redirect
Sheffield University

values:
/wiki/Competitive_antagonist
mw-redirect
Competitive antagonist

values:
/wiki/Antibiotic_resistance
mw-redirect
Antibiotic resistance

values: nowraplinks collapsible autocollapse navbox-inner

values:
nofollow
external text
//www.ncbi.nlm.nih.gov/pubmed/22360418

values: Category:CS1 German-language sources (de)

values: Category:All articles with dead external links

values: Category:Articles with dead external links from September 2017

values: Category:Articles with permanently dead external links

values: Category:All articles with unsourced statements

values: Category:Articles with unsourced statements from February 2018

values: Category:Wikipedia external links cleanup from May 2016

values: Category:Wikipedia spam cleanup from May 2016

values: Discussion about edits from this IP address [ctrl-alt-n]

values: A list of edits made from this IP address [ctrl-alt-y]

values: You're encouraged to log in; however, it's not mandatory. [ctrl-alt-o]

values:
/wiki/Pharmacokinetics
View the content page [ctrl-alt-c]
c

values: Discussion about the content page [ctrl-alt-t]

values: p-namespaces navigation vectorTabs p-namespaces-label

values:
p-variants
navigation
vectorMenu emptyPortlet
p-variants-label

values: Past revisions of this page [ctrl-alt-h]

values: p-views navigation vectorTabs p-views-label

values:
p-cactions
navigation
vectorMenu emptyPortlet
p-cactions-label

values:
mw-wiki-logo
/wiki/Main_Page
Visit the main page

values:
/wiki/Main_Page
Visit the main page [ctrl-alt-z]
z

values: portal navigation p-navigation p-navigation-label

values: Guidance on how to use and edit Wikipedia

values: Printable version of this page [ctrl-alt-p]

values: portal navigation p-wikibase-otherprojects p-wikibase-otherprojects-label

values: حركية دوائية – Arabic

values: Фармакокинетика – Bulgarian

values: Φαρμακοκινητική – Greek

values: interlanguage-link interwiki-es badge-Q17437798 badge-goodarticle

values: فارماکوکینتیک – Persian

values: 약물동태학 – Korean

values: פרמקוקינטיקה – Hebrew

values: interlanguage-link interwiki-lv badge-Q17437798 badge-goodarticle

values: Фармакокинетика – Macedonian

values: फार्माकोकायनेटिक्स – Marathi

values: Фармакокинетика – Russian

values: เภสัชจลนศาสตร์ – Thai

values: Фармакокінетика – Ukrainian

values: 药物代谢动力学 – Chinese

values:
suggestions
display: none; font-size: 13px;

values: mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject page-Pharmacokinetics rootpage-Pharmacokinetics skin-vector action-view